$80.6
+1.93
(+2.45%)▲
1.88%
Downside
Day's Volatility :2.75%
Upside
0.89%
36.2%
Downside
52 Weeks Volatility :39.91%
Upside
5.81%
Period | Bio-techne Corp. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 22.81% | 6.5% | 5.9% |
6 Months | 8.32% | 7.1% | 10.4% |
1 Year | -7.43% | 9.8% | 18.2% |
3 Years | -33.35% | 14.2% | 22.1% |
Market Capitalization | 12.2B |
Book Value | $12.79 |
Dividend Share | 0.32 |
Dividend Yield | 0.41% |
Earnings Per Share (EPS) | 1.25 |
PE Ratio | 62.09 |
PEG Ratio | 1.15 |
Wall Street Target Price | 83.86 |
Profit Margin | 17.59% |
Operating Margin TTM | 23.74% |
Return On Assets TTM | 6.11% |
Return On Equity TTM | 10.4% |
Revenue TTM | 1.2B |
Revenue Per Share TTM | 7.32 |
Quarterly Revenue Growth YOY | 3.2% |
Gross Profit TTM | 770.2M |
EBITDA | 326.3M |
Diluted Eps TTM | 1.25 |
Quarterly Earnings Growth YOY | -0.28 |
EPS Estimate Current Year | 1.78 |
EPS Estimate Next Year | 2.02 |
EPS Estimate Current Quarter | 0.45 |
EPS Estimate Next Quarter | 0.5 |
What analysts predicted
Upside of 4.04%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 643.0M | ↑ 14.21% |
Net Income | 125.4M | ↑ 62.19% |
Net Profit Margin | 19.49% | ↑ 5.76% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 714.0M | ↑ 11.04% |
Net Income | 96.1M | ↓ 23.36% |
Net Profit Margin | 13.46% | ↓ 6.03% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 738.7M | ↑ 3.46% |
Net Income | 229.3M | ↑ 138.67% |
Net Profit Margin | 31.04% | ↑ 17.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 931.0M | ↑ 26.04% |
Net Income | 140.4M | ↓ 38.76% |
Net Profit Margin | 15.08% | ↓ 15.96% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 18.75% |
Net Income | 272.1M | ↑ 93.75% |
Net Profit Margin | 24.61% | ↑ 9.53% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 2.81% |
Net Income | 285.3M | ↑ 4.86% |
Net Profit Margin | 25.1% | ↑ 0.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 271.6M | ↑ 0.71% |
Net Income | 50.0M | ↓ 44.16% |
Net Profit Margin | 18.41% | ↓ 14.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 294.1M | ↑ 8.31% |
Net Income | 70.2M | ↑ 40.42% |
Net Profit Margin | 23.87% | ↑ 5.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 301.3M | ↑ 2.44% |
Net Income | 75.5M | ↑ 7.5% |
Net Profit Margin | 25.05% | ↑ 1.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 276.9M | ↓ 8.09% |
Net Income | 51.0M | ↓ 32.45% |
Net Profit Margin | 18.41% | ↓ 6.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 272.6M | ↓ 1.57% |
Net Income | 27.5M | ↓ 46.14% |
Net Profit Margin | 10.08% | ↓ 8.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 303.4M | ↑ 11.31% |
Net Income | 49.1M | ↑ 78.62% |
Net Profit Margin | 16.17% | ↑ 6.09% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 2.35% |
Total Liabilities | 514.1M | ↓ 15.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 18.28% |
Total Liabilities | 718.8M | ↑ 39.83% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 7.6% |
Total Liabilities | 646.4M | ↓ 10.08% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 11.61% |
Total Liabilities | 691.7M | ↑ 7.01% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 1.41% |
Total Liabilities | 593.8M | ↓ 14.16% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 14.99% |
Total Liabilities | 672.2M | ↑ 13.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↑ 0.54% |
Total Liabilities | 536.3M | ↓ 10.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 10.0% |
Total Liabilities | 710.0M | ↑ 32.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 1.5% |
Total Liabilities | 672.2M | ↓ 5.33% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↑ 4.42% |
Total Liabilities | 757.6M | ↑ 12.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↓ 0.89% |
Total Liabilities | 767.2M | ↑ 1.26% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↓ 0.35% |
Total Liabilities | 706.8M | ↓ 7.87% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 170.4M | ↑ 18.77% |
Investing Cash Flow | -38.7M | ↓ 87.35% |
Financing Cash Flow | -99.2M | ↓ 152.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 181.6M | ↑ 6.6% |
Investing Cash Flow | -336.8M | ↑ 770.01% |
Financing Cash Flow | 134.4M | ↓ 235.48% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 205.2M | ↑ 12.99% |
Investing Cash Flow | 27.1M | ↓ 108.04% |
Financing Cash Flow | -183.8M | ↓ 236.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 352.2M | ↑ 71.61% |
Investing Cash Flow | -243.5M | ↓ 998.75% |
Financing Cash Flow | -62.6M | ↓ 65.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 325.3M | ↓ 7.64% |
Investing Cash Flow | -96.9M | ↓ 60.23% |
Financing Cash Flow | -242.9M | ↑ 288.25% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 254.4M | ↓ 21.79% |
Investing Cash Flow | -265.6M | ↑ 174.29% |
Financing Cash Flow | 22.6M | ↓ 109.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 64.4M | ↑ 14.81% |
Investing Cash Flow | -109.0K | ↓ 99.45% |
Financing Cash Flow | -72.2M | ↑ 126.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 50.5M | ↓ 21.51% |
Investing Cash Flow | -241.1M | ↑ 221088.99% |
Financing Cash Flow | 150.8M | ↓ 308.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 83.4M | ↑ 65.02% |
Investing Cash Flow | -4.8M | ↓ 98.03% |
Financing Cash Flow | -24.2M | ↓ 116.06% |
Sell
Neutral
Buy
Bio-techne Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bio-techne Corp. | 9.11% | 8.32% | -7.43% | -33.35% | 46.63% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bio-techne Corp. | 62.09 | 62.09 | 1.15 | 1.78 | 0.1 | 0.06 | 0.0 | 12.79 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bio-techne Corp. | Buy | $12.2B | 46.63% | 62.09 | 17.59% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Bio-techne Corp.
Revenue is up for the last 2 quarters, 272.59M → 303.42M (in $), with an average increase of 10.2% per quarter
Netprofit is up for the last 2 quarters, 27.46M → 49.05M (in $), with an average increase of 44.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 69.0%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 219.8%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
T. Rowe Price Associates, Inc.
BAMCO Inc
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Bio-techne Corp. has declared dividend of $0.08
Read Morebio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
Organization | Bio-techne Corp. |
Employees | 3200 |
CEO | Mr. Kim Kelderman |
Industry | Health Technology |